RT期刊文章SR电子T1 18 f - av - 1451额颞叶痴呆谱系障碍(S35.003)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP S35.003 VO 88是16首页补充A1理查德·蔡A1 Alexandre Bejanin A1丹尼尔Schonhaut A1里克Ossenkoppele A1詹姆斯·奥尼尔A1 Mustafa Janabi A1苏珊娜贝克A1 Andreas Lazaris A1 Nagehan Ayakta A1 Gautam Tammewar A1玛丽亚Gorno Tempini A1布鲁斯·米勒A1亚当拳击手A1威廉Jagust A1吉尔Rabinovici年2017 UL //www.ez-admanager.com/content/88/16_Supplement/S35.003.abstract AB目的:确定的效用τ宠物配体18 f - av - 1451额颞叶痴呆(FTD)谱系障碍。背景:异常聚合τ蛋白是一个潜在的FTD谱系障碍的病理特征。准确识别将临床试验的关键。设计/方法:我们评估行为变异额颞叶痴呆(bvFTD, n = 5),迟滞型变体原发性进行性失语(nfvPPA, n = 9),语义变体原发性进行性失语(svPPA, n = 2),进步supranculear麻痹(PSP, n = 10), corticobasal综合症(CBS, n = 9), C9ORF72突变(n = 3), MAPT突变携带者(n = 5)和amyloid-negative正常对照组(NC, n = 22)和18 f - av - 1451的宠物。18 f av - 1451图像总结,标准摄入值比率计算t = 80 - 100分钟的使用意味着活动小脑灰质区域(不含齿状核)作为参考。结果:数控显示不同程度的吸收在内侧颞叶皮层中脑、基底神经节和小脑。症状MAPT运营商(CDR 1 - 2)显示增加额颞叶18 f - av - 1451相比,吸收轻度或无症状携带者(CDR 0 - 0.5)。在两个bvFTD情况下,吸收的额颞叶和顶叶区域。在PSP和nfvPPA voxel-wise相比数控显示增加吸收双边在苍白球(p (FWE) < 0.05)、壳核、丘脑、丘脑核背侧中脑、小脑齿状核(p < 0.001未修正的)PSP和双边额盖,在nfvPPA额中回(p < 0.001未调整的)。CBS主题显示不同程度的核吸收,苍白球和白质。吸收偏侧性匹配一侧nfvPPA和哥伦比亚广播公司(CBS)症状。吸收是双边侧,颞极svPPA情况下,和额极C9ORF72病例。Conclusions: In summary, elevated 18F-AV-1451 uptake matched the expected distribution of tau pathology in FTD spectrum disorders. However, elevated retention in subcortical regions in NC and neurodegenerative regions in patients with predicted TDP-43 pathology raise questions about specificity of binding. The 18F-AV-1451 tracer warrants further exploration in FTD spectrum disorders.Study Supported by:Avid Radiopharmaceuticals enabled use of the [18F]AV-1451 tracer but did not provide direct funding This study was supported by the Tau ConsortiumDisclosure: Dr. Tsai has nothing to disclose. Dr. Bejanin has nothing to disclose. Dr. Schonhaut has nothing to disclose. Dr. Ossenkoppele has nothing to disclose. Dr. O'Neil has nothing to disclose. Dr. Janabi has nothing to disclose. Dr. Baker has nothing to disclose. Dr. Lazaris has nothing to disclose. Dr. Ayakta has nothing to disclose. Dr. Tammewar has nothing to disclose. Dr. Tempini has received personal compensation in an editorial capacity from Neuroimage Clinical. Dr. Miller has nothing to disclose. Dr. Boxer has received personal compensation for activities with Abbvie, Asceneuron, Janssen, Merck for consulting. Dr. Jagust has received personal compensation for activities with Genentech Inc., Synarc, Janssen Alzheimer Immunotherapy, TauRx, and Siemens as a consultant. Dr. Rabinovici has received personal compensation for activities with Eisai, Roche, Lundbeck, and Putnam as a speaker or consultant. Dr. Rabinovici has received research support from NIH, Alzheimer's Association, Tau Consortium, American College of Radiology, Michael J Fox Foundation, Association for Frontotemporal Degneration, Avid Radiopharmaceuticals/Eli Lilly, GE Healthcare, and Piramal Imaging.